Cells · 2023 · 12 citations · 29 references
MedicineCancer BiologyOncologyMolecular DiagnosticsMolecular OncologyPrecision OncologyCancer BiomarkersCancer Molecular DiagnosticsCirculating Tumor CellsImmuno-oncology BiomarkersMolecular Tumor ProfilingPancreatic CancerCirculating Tumor Cell BiomarkersCirculating Tumor Cell EnumerationCirculating Tumor Cell MonitoringNiraparib TherapyPoly(adp-ribose) Polymerase InhibitionPoly(adp-ribose) Polymerase InhibitorsTreatment Response BiomarkersTumor Response Prediction
There is a high clinical unmet need to improve outcomes for pancreatic ductal adenocarcinoma (PDAC) patients, either with the discovery of new therapies or biomarkers that can track response to treatment more efficiently than imaging. We report an innovative approach that will generate renewed interest in using circulating tumor cells (CTCs) to monitor treatment efficacy, which, in this case, used PDAC patients receiving an exploratory new therapy, poly ADP-ribose polymerase inhibitor (PARPi)—niraparib—as a case study. CTCs were enumerated from whole blood using a microfluidic approach that affinity captures epithelial and mesenchymal CTCs using anti-EpCAM and anti-FAPα monoclonal antibodies, respectively. These antibodies were poised on the surface of two separate microfluidic devices to discretely capture each subpopulation for interrogation. The isolated CTCs were enumerated using immunophenotyping to produce a numerical ratio consisting of the number of mesenchymal to epithelial CTCs (denoted “Φ”), which was used as an indicator of response to therapy, as determined using computed tomography (CT). A decreasing value of Φ during treatment was indicative of tumor response to the PARPi and was observed in 88% of the enrolled patients (n = 31). Changes in Φ during longitudinal testing were a better predictor of treatment response than the current standard CA19-9. We were able to differentiate between responders and non-responders using ΔΦ (p = 0.0093) with higher confidence than CA19-9 (p = 0.033). For CA19-9 non-producers, ΔΦ correctly predicted the outcome in 72% of the PDAC patients. Sequencing of the gDNA extracted from affinity-selected CTC subpopulations provided information that could be used for patient enrollment into the clinical trial based on their tumor mutational status in DNA repair genes.
29
Sue Richards, Nazneen Aziz, Sherri J. Bale et al. · Genetics in Medicine · 2015 · 32.2K citations · Full text
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Sunitha Nagrath, Lecia V. Sequist, Shyamala Maheswaran et al. · Nature · 2007 · 3.5K citations · Full text
Medicine, Cancer Biology, Oncology +15
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell, Marina Pajic, Ann‐Marie Patch et al. · Nature · 2015 · 2.7K citations · Full text